Tag: pharmaceuticals
-
Three Drug Makers Partner with NIH to Expand Therapies
National Institutes of Health and three pharmaceutical manufacturers will collaborate on research to find new treatments for diseases from currently approved drugs. Pfizer, AstraZeneca, and Eli Lilly and Company will make at least 20 of their existing compounds available for this research to NIH’s National Center for Advancing Translational Sciences (NCATS). The program, called Discovering…
-
SBIR Grant Awarded for Infant Respiratory Vaccine
GenVec Inc. in Gaithersburg, Maryland received a Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases at National Institutes of Health to help fund development of the company’s vaccine against respiratory syncytial virus. The phase 1 SBIR grant is valued at some $590,000. Respiratory syncytial virus (RSV) infects…
-
Nanotech Solution Helps Enable Cancer Drug Delivery
Researchers at University of North Carolina medical school in Chapel Hill have found a process for delivering the cancer drug wortmannin using nanoscale particles, a drug that had not been deliverable using traditional methods. Their findings appear online in the journal Proceedings of the National Academy of Sciences (paid subscription required). Wortmannin had been considered…
-
Clinical Trial to Test Varied Hypertension Drug Dosage
Researchers at University of Rochester Medical Center in New York are testing if a lower dose of an common blood pressure medicine can provide the same benefits as a standard dose in people with mild hypertension. The new clinical trial is funded with a $1.9 million grant from the National Heart Lung and Blood Institute,…
-
White House Issues Outline for Bioscience-Based Economy
The Office of Science and Technology Policy in the White House today released a national Bioeconomy Blueprint that it says will harness biological research to address national priorities. The plan outlines actions to be undertaken by federal agencies. No mention is made of new legislation, although the administration’s latest budget submission identified as a priority…
-
Patent Issued on Antibody for Brain, Spinal Cord Treatments
Lpath Inc., a biotechnology company in San Diego, has been awarded a patent for its monoclonal antibody against lysophosphatidic acid, a factor in neurological disorders such as traumatic brain and spinal cord injuries. Patent 8,158,124 was issued last week by the U.S. Patent and Trademark Office to four inventors, including Lpath’s chief scientist Roger Sabbadini,…
-
Biopharm Lands $25M Venture Funding for Phase 3 Trial
Argos Therapeutics Inc., a biopharmaceutical company in Durham, North Carolina, says it secured $25 million in series D venture financing, the fourth funding installment after initial start-up. The funds are expected to support a planned clinical trial of Argos Therapeutics’ immunotherapy for metastatic renal cell carcinoma, a form of kidney cancer. The financing was led…
-
Microemulsion Shows Promise for Extending Vaccine Shelf Life
A U.S. Army medical researcher has devised a new process for mixing vaccine ingredients with the potential for extending the shelf life of vaccines. Maj. Jean Muderhwa (pictured left) , a deputy laboratory director at the Brooke Army Medical Center in San Antonio, presented his findings yesterday at a meeting of the American Society for…
-
AstraZeneca to Acquire Biotech for $1.26 Billion
The global pharmaceutical maker AstraZeneca says it will acquire Ardea Biosciences Inc., a biotechnology company in San Diego developing small molecule therapies. The deal is valued at $1.26 billion, with AstraZeneca paying $32.00 a share, a 54 percent premium over Ardea’s closing price on Friday 20 April. Ardea’s most advanced drug candidate is lesinurad taken…
-
U.S. Venture Deals, Dollars Decline in Q1 2012
Companies in the U.S. raised less money in fewer venture capital deals during the first three months of 2012 compared to the same period last year, according to data compiled by Dow Jones VentureSource. Some science-based sectors fared better than others during this period, while venture capital (VC) investors generally showed more interest this year…